Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 3/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.38 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.38 |
| ▸ | RAF1 | P04049 | 3/20 | 0.37 |
| ▸ | BRAF | P15056 | 3/20 | 0.37 |
| ▸ | USP7 | Q93009 | 2/20 | 0.36 |
| ▸ | FYN | P06241 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | PRKCI | P41743 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19661652 | 0.88 | DHODH (0.38) | DHODHRAF1BRAFMAPK1PRKCI | |
| SCHEMBL18306335 | 0.86 | DHODH (0.38) | DHODHTGFBR1FYNMAPK1KDM1A | |
| SCHEMBL17177314 | 0.84 | DHODH (0.36) | DHODH | |
| SCHEMBL17177309 | 0.83 | DHODH (0.33) | DHODH | |
| SCHEMBL18306350 | 0.80 | TGFBR1 (0.39) | TGFBR1TGFBR2USP7FYNMAP4K4 | |
| SCHEMBL15638460 | 0.78 | ROCK2 (0.48) | DHODHMAPK1MAP4K4CHEK2 | |
| SCHEMBL18306347 | 0.74 | ADORA2B (0.34) | TGFBR1 | |
| SCHEMBL17177311 | 0.71 | BTK (0.41) | TGFBR1RAF1FYNMAPK1HSP90AA1 | |
| SCHEMBL18306341 | 0.69 | ADORA1 (0.42) | TGFBR1FYNKDM1AMAP4K4 | |
| SCHEMBL18306360 | 0.69 | IRAK4 (0.35) | BRAFKDM1AMAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10858335-B2 | 2,3-Disubstituted pyridine compounds as TGF-β inhibitors and methods of use | RIGEL PHARMACEUTICALS, INC. (US) | 2020-12-08 | — | — | US | disclosed |
| US-20190284155-A1 | 2,3-Disubstituted Pyridine Compounds as TGF-Beta Inhibitors and Methods of Use | RIGEL PHARMACEUTICALS, INC. (US) | 2019-09-19 | — | — | US | disclosed |
| US-10233170-B2 | 2,3-disubstituted pyridine compounds as TGF-beta inhibitors and methods of use | RIGEL PHARMACEUTICALS, INC. (US) | 2019-03-19 | — | — | US | disclosed |
| US-20170342048-A1 | GDF-8 Inhibitors | MIDCAP FINANCIAL TRUST | 2017-11-30 | — | — | US | disclosed |
| US-20170342048-A1 | GDF-8 Inhibitors | MIDCAP FINANCIAL TRUST | 2017-11-30 | — | — | US | disclosed |
| US-9518040-B2 | GDF-8 inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2016-12-13 | — | — | US | disclosed |
| US-9518040-B2 | GDF-8 inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2016-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10233170-B2 | 2,3-disubstituted pyridine compounds as TGF-beta inhibitors and methods of use | TGFBR1, TGFBR2, ACVR1 | DHODH 1945/4885TGFBR1 1/4885TGFBR2 2/4885 |
| US-20170342048-A1 | GDF-8 Inhibitors | MSTN, MYOF, CXCL8 | DHODH 4754/4885TGFBR1 128/4885TGFBR2 112/4885 |
| US-10858335-B2 | 2,3-Disubstituted pyridine compounds as TGF-β inhibitors and methods of use | SMAD3, TGFBR1, TGFBR2 | DHODH 2127/4885TGFBR1 2/4885TGFBR2 3/4885 |
| US-20190284155-A1 | 2,3-Disubstituted Pyridine Compounds as TGF-Beta Inhibitors and Methods of Use | TGFBR2, ACVR1, TGFBR1 | DHODH 2040/4885TGFBR1 3/4885TGFBR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.